	3	u pius	Sign (			Patent	Approve	ed for u	through 09/30/00 OMP	7 (12/97) 0651-0032	
Other the Tap rwork Reduction Act of 1995, no Cersons are required						Patent and Trademark Orfice: U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it displays a valid OMB control number.					
						Complete if Known					
SEP 0 7 200 FEE TRANSPITATAL 7 200 2					Application Number				09/834,229		
SEP 07	2001	FEE 1	PRANSE	11 1900 A 10 7 2001 (2)	Filing	g Date			April 12, 2001		
			<u> </u>		First	Named I	nventor		Suad Efendic		
Note Effective November 10, 1998.  Patent fees are subject to annual revision.						Art Uni	t				
					Examin	ner Name					
MICTORY	AMOUNT			(\$4,10,00×	Attorn	ney Dock	et Numbe	er	X-10822A		
METHOD OF PAYMENT (check one)							FEE	CALCUL	ATION (continued)		
	` <del></del>			-	3. A	DDITION					
1.		The Comm:	issioner i ndicated f	s hereby authorized to ees and credit any	Large	Entity	Small	Entity			
		overpayme	ents to:	sees and credit any	Fee Code	Fee	Fee	Fee	Fee Description	Fee	
	posit	05-0	840		105	(\$) <b>130</b>	Code 205	(\$) 65	Surcharge-late filing fee or	Paid	
	count mber	" "	010			-50	203	03	oath		
Deposit Eli Lilly and Company					127	50	227	25	Surcharge-late provisional		
Ac	count Name			and company	<b>↓</b> ·	••		43	filing fee or cover sheet.	L.	
l x	Charge	Any		Charge the Issue Fee Set	139	120	130	. 120			
	Additi	onal Fee		in 37 CFR 1.18 at the	139	130	139	130	Non-English specification		
1		ed Under 1.16 and	1	Mailing of the Notice of Allowance							
	1.17			Allowance							
2.	'	Payment E	nclosed:		147	2,520	147	2,520	For filing a request for		
1					1				reexamination	L	
l.	Γ	Ch	neck	Money Other	112	920*	112	920*	Requesting publication of SIR		
Ī	L		<u> </u>	Order	1				prior to Examiner action		
<u> </u>					113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		
1		FEE (	CALCULI	ATION	115	110	215	55	Extension for reply within	110	
					116	390	216	195	first month Extension for reply within		
1.	mrr re	7G BBB							second month		
		ig fee			117	890	217	445	Extension for reply within third month		
Large Fee	Entity Fee	Small Fee	Entity Fee	Fee Fee	118	1,390	218	695	Extension for reply within	<del>  </del>	
Code	(\$)	Code	(\$)	Description Paid	i				fourth month		
101	710	201	355	Utility filing fee	128	1,890	228	945	Extension for reply within		
106	320	206	160	Design	119	310	219	155	fifth month Notice of Appeal		
107	490	207	245	filing fee						1	
]	490	207	245	Plant filing fee	120	310	220	155	Filing a brief in support of an appeal		
108	710	208	355	Rojesus							
1		200	333	Reissue filing fee	121	270	221	135	Request for oral hearing		
- 114	150	214	75	Provisional	138	1,510	138	1,510	Petition to institute a public	<b>——</b>	
-				filing fee	140	110	240	55	use proceeding Petition to revive-unavoidable		
	នប	BTOTAL	(1) [	\$)	141	1,240	241	620	Petition to revive-unavoidable Petition to revive-		
					140				unintentional		
2.	CLAII	MS	Extr	Fee from Fee Paid	142 143	1,210 430	242 243	605 215	Utility issue fee (or reissue)		
Total		-20**=	a	below		430	243	215	Design Issue Fee	1 1	
Claims		-20=		X 18 =	144	580	244	290	Plant Issue Fee		
Indepen Claims	dent	-3**=	1 7	x 80 =	122	130	122	130	Petitions to the Commissioner	<b></b>	
Multipl	e Dependent	Claims	-	270 =	123	50	122	EO			
(fir	st time)						123	50	Petitions related to provisional applications	] ] ]	
					126	240	126	240	Submission of Information Disclosure Stmt.		
1					581	40	581	40	Recording each patent	<b>├</b> ─┤	
1_									assignment per property (times number of properties)		
Large Fee	Entity Fee	Small Fee	Entity Fee	Fee Description	146	710	246	355	Filing a submission after final	<u>├</u> ──┤ │	
Code	(\$)	Code	(\$)						rejection (37 CFR 1.129(a))	, , ,	
103	18	203	9	Claims in excess of 20	149	710	249	355	For each additional invention	<del>  </del>	
]									to be examined (37 CFR 1.129(b))		
102	80	202	39	Independent claims in excess of 3	179	710	279	355	Request for Continued	├ <del></del> -	
104	270	204	135	Multiple dependent	169	900	169	900	Examination (RCE) Request for expedited	└──┤ │	
1				claim			103	200	examination of a design		
109	78	209	39	Reissue independent	Other fe	e (specif	fv)		application		
-				claims over original patent		· (Spoot)	-11			1 1	
110	18	210	9	Reissue claims in	Other fo	e (specif	(v)			L	
1				excess of 20 and over original patent		(Dpccii	-17				
SUBTOTAL (2) (\$)						by Basic Fi	iling Fee	Paid	STIPMOMAT (3) (4) 110 00		
**or number previously paid, if greater; For Reissues, see above							5		<b>SUBTOTAL (3)</b> (\$)110.00	1 1	
	TED BY	sues, see	apove						Complete life : 1		
Typed N		Mark J	Ştewart,	Ph.D.					Complete (if applicable)		
Signatu		2701		16. 1					Reg. Number 43,936		
CERTIFICATE OF MAILING											
I here	by certi	fy that	t this	correspondence is bei	na deno	eited wi	th Imit	od Char-	s Postal Service as first		
			dress	od to: Assistant Comm	nissione	r of Pat	ents W	eu state ashinata	s rostal Service as first	class	
mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231, on the date appearing below.											
<u> </u>											
By Date											





INTED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/834,229

04/12/2001

Suad Efendic

X-10822A

**CONFIRMATION NO. 4450** 

**FORMALITIES LETTER** 

OC000000006144250\*

Mark J. Stewart, Ph.D. √ Eli Lilly and Company Lilly Corporate Center Patent Division DC: 1104 Indianapolis, IN 46285

Que: August 4,2001

Date Mailed: 06/04/2001

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

RECEIVED

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

JUN 08 2001

ELI LILLY AND CO. PATENT DIVISION

A copy of this notice MUST be returned with the reply,

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY